企業プロフィール
Cellectar Biosciences 株価・ニュース・カタリスト
- ティッカー:
- CLRB
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
2.56 USD (-1.54%)
終値
最終更新: 2026年8月17日
21.9M USD
時価総額
株価変動の要因
As of Aug 17, 2026, CLRB closed down 1.54% at $2.56. No new same-company headline was identified in the current news window.
企業概要
Phospholipid Drug Conjugate Platform
Cellectar Biosciences develops cancer therapies using its Phospholipid Drug Conjugate platform, which is designed to deliver radioisotopes selectively to malignant cells while limiting off-target exposure.
Iopofosine I 131
Iopofosine I 131 is the company’s lead radioconjugate and has produced clinical evidence in relapsed or refractory Waldenström macroglobulinemia. It has also been studied in multiple myeloma and central nervous system lymphoma.
CLR 125 Solid-Tumor Program
CLR 125 carries the Auger-emitting isotope iodine-125 and is being evaluated initially in triple-negative breast cancer, with potential application in lung and colorectal cancers.
Regulatory Strategy
Cellectar plans a confirmatory study of iopofosine in Waldenström macroglobulinemia to support a potential FDA filing under the Accelerated Approval pathway.
今後のカタリスト
- Initiation of enrollment in the confirmatory Phase 3 iopofosine I 131 study in Waldenström macroglobulinemia.
- NDA submission for iopofosine I 131 under the accelerated-approval pathway in mid-2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。